¹⁷⁷Lu-edotreotide — Investigational Agent
Other · NDA/BLA Submitted · ITM Isotope Technologies Munich SE
Mechanism of Action
Non-carrier-added (n.c.a.) radioligand therapy consisting of the somatostatin analogue edotreotide (DOTA-TOC) conjugated to the beta-emitting radioisotope lutetium-177 (¹⁷⁷Lu). Edotreotide binds somatostatin receptor subtypes 2 and 5 (SSTR2/5) overexpressed on neuroendocrine tumor cells with high affinity; after receptor-mediated internalization, the ¹⁷⁷Lu payload delivers targeted beta radiation (tissue penetration ~1–2 mm, physical half-life ~6.7 days) directly to tumor cells and the surrounding microenvironment. The "non-carrier-added" production process (no stable lutetium added) yields…
Investigational Indications
- Somatostatin receptor-positive (SSR+) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) — well-differentiated, progressive, PRRT-naïve (Phase 3 COMPETE trial)
- SSR+ neuroendocrine tumors of other primary sites (bronchial, unknown primary) — exploratory